JOWIN BIOPHARMA INC
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
1. New Drug Development
2. Drug Delivery Systems
3. Pharmaceutical Engineering Technology
4. Targeted Drug Development
(The content above was translated by AI.)
2. Drug Delivery Systems
3. Pharmaceutical Engineering Technology
4. Targeted Drug Development
(The content above was translated by AI.)
Founded Year
2015
Unified Business No.
24726307
Status
Active
Number of Employees
0
Total Paid-in
Capital
78,170,000 (NT$)
Location of Company
Taiwan
, New Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
JOWIN BIOPHARMA INC is a biotechnology company engaged in the research and development of novel drugs and anti-aging health foods. It was founded in February 2015 by Dr. Wen-Chin Chiang, a chief drug R&D expert from the major US pharmaceutical company Bristol Myers Squibb (BMS). With a rigorous scientific and professional attitude, the company develops outstanding and safe medicines and health foods, with the mission of improving human health and quality of life. Developing health supplements and skincare products from a pharmaceutical perspective and to pharmaceutical standards, the company integrates upstream raw materials to downstream processing, simultaneously upgrading related industries and product quality. Since medical and pharmaceutical products are vital to human health and safety, JOWIN BIOPHARMA INC advocates replacing exaggerated and false publicity with scientific research data and figures, strictly controlling the entire process from raw material acquisition to product R&D and manufacturing. In addition to basic food safety testing, active ingredients are used as the control benchmark to maintain consistent product efficacy, and "scientific validation" is used to confirm that the products provide beneficial and effective treatment for indications, thereby achieving the effects of eliminating disease and strengthening the body.
In terms of novel drug development, our research team has successfully developed a PDC (peptide-drug-conjugate) technology platform and an ASD (amorphous solid dispersion) technology platform. PDC technology uses peptides to carry drugs to recognize and bind to receptors on the surface of cancer cells and inhibit their growth, currently primarily applied to non-small cell lung cancer. Meanwhile, ASD technology improves the solubility of small molecule drugs, and is a mature and effective technology. We welcome guidance and cooperation from industry leaders and experts from all walks of life.
(The content above was translated by AI.)
In terms of novel drug development, our research team has successfully developed a PDC (peptide-drug-conjugate) technology platform and an ASD (amorphous solid dispersion) technology platform. PDC technology uses peptides to carry drugs to recognize and bind to receptors on the surface of cancer cells and inhibit their growth, currently primarily applied to non-small cell lung cancer. Meanwhile, ASD technology improves the solubility of small molecule drugs, and is a mature and effective technology. We welcome guidance and cooperation from industry leaders and experts from all walks of life.
(The content above was translated by AI.)
